These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 30410558)
1. Shenqi Fuzheng Injection Reverses Cisplatin Resistance through Mitofusin-2-Mediated Cell Cycle Arrest and Apoptosis in A549/DDP Cells. Xiong Y; Zhao Q; Gu L; Liu C; Wang C Evid Based Complement Alternat Med; 2018; 2018():8258246. PubMed ID: 30410558 [TBL] [Abstract][Full Text] [Related]
2. Shenmai injection enhances cisplatin-induced apoptosis through regulation of Mfn2-dependent mitochondrial dynamics in lung adenocarcinoma A549/DDP cells. Chen Y; Sun Y; Zhao Q; Liu C; Wang C Cancer Drug Resist; 2021; 4(4):1047-1060. PubMed ID: 35582383 [No Abstract] [Full Text] [Related]
3. β-elemene reverses the drug resistance of lung cancer A549/DDP cells via the mitochondrial apoptosis pathway. Yao CC; Tu YR; Jiang J; Ye SF; Du HX; Zhang Y Oncol Rep; 2014 May; 31(5):2131-8. PubMed ID: 24627125 [TBL] [Abstract][Full Text] [Related]
4. Anti-apoptotic brain and reproductive organ-expressed proteins enhance cisplatin resistance in lung cancer cells via the protein kinase B signaling pathway. Li Y; Qi K; Zu L; Wang M; Wang Y; Zhou Q Thorac Cancer; 2016 Mar; 7(2):190-8. PubMed ID: 27042221 [TBL] [Abstract][Full Text] [Related]
5. Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. Zhang W; Zhou H; Yu Y; Li J; Li H; Jiang D; Chen Z; Yang D; Xu Z; Yu Z Onco Targets Ther; 2016; 9():3359-68. PubMed ID: 27330316 [TBL] [Abstract][Full Text] [Related]
6. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin. Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2. Xie J; Yu F; Li D; Zhu X; Zhang X; Lv Z Tumour Biol; 2016 Jan; 37(1):1197-204. PubMed ID: 26282001 [TBL] [Abstract][Full Text] [Related]
8. Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis. Zhang R; Li Y; Wang Z; Chen L; Dong X; Nie X Tumour Biol; 2015 Nov; 36(11):8585-92. PubMed ID: 26040768 [TBL] [Abstract][Full Text] [Related]
9. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway. Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285 [TBL] [Abstract][Full Text] [Related]
10. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer. Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469 [TBL] [Abstract][Full Text] [Related]
11. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression. Sui C; Meng F; Li Y; Jiang Y J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928 [TBL] [Abstract][Full Text] [Related]
12. Calotropin from Asclepias curasavica induces cell cycle arrest and apoptosis in cisplatin-resistant lung cancer cells. Mo EP; Zhang RR; Xu J; Zhang H; Wang XX; Tan QT; Liu FL; Jiang RW; Cai SH Biochem Biophys Res Commun; 2016 Sep; 478(2):710-5. PubMed ID: 27498029 [TBL] [Abstract][Full Text] [Related]
13. Mitochondrial Dynamics Mediated by DRP1 and MFN2 Contributes to Cisplatin Chemoresistance in Human Ovarian Cancer SKOV3 cells. Zou GP; Yu CX; Shi SL; Li QG; Wang XH; Qu XH; Yang ZJ; Yao WR; Yan DD; Jiang LP; Wan YY; Han XJ J Cancer; 2021; 12(24):7358-7373. PubMed ID: 35003356 [TBL] [Abstract][Full Text] [Related]
14. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells. Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854 [TBL] [Abstract][Full Text] [Related]
15. The CK2 inhibitor CX4945 reverses cisplatin resistance in the A549/DDP human lung adenocarcinoma cell line. Jin C; Song P; Pang J Oncol Lett; 2019 Oct; 18(4):3845-3856. PubMed ID: 31579410 [TBL] [Abstract][Full Text] [Related]
16. [The roles of holothurian glycosaminoglycan combined with cisplatin on proliferation and chemotherapeutic response in A549 human lung adenocarcinoma cell]. Jin Q; Zhu XH; Lin CZ; Zhang H; Cao YW; Ding XQ; Lyu ZH Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):252-257. PubMed ID: 29730910 [No Abstract] [Full Text] [Related]
17. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression. Xia A; Li H; Li R; Lu L; Wu X Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933 [TBL] [Abstract][Full Text] [Related]
18. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest. Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells. Gao Y; Liu Z; Zhang X; He J; Pan Y; Hao F; Xie L; Li Q; Qiu X; Wang E Cancer Lett; 2013 Aug; 336(1):231-9. PubMed ID: 23673211 [TBL] [Abstract][Full Text] [Related]
20. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs). Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]